Abstract. To 
release, we examined in conscious rats the effects of intraventricular (ivt) administrations of catecholamine antagonists on plasma AVP responses to ivt applications of its agonists and ANG II. Plasma AVP was determined by RIA using trunk blood collected after decapitation. Dopamine (0.15 \g=m\mol),phenylephrine (an alpha-adrenergic agonist, 0.15 \g=m\mol) or ANG II (48.2 pmol) augmented plasma AVP 90 sec after the injection, whereas after isoproterenol (a beta-adrenergic agonist, 0.15 \g=m\mol)plasma AVP was unaffected. The plasma AVP responses to both dopamine and ANG II were significantly (P < 0.01) inhibited by haloperidol (a dopamine blocker, 0.15 \g=m\mol)given 10 min before administration of these agents. Pre-administration of phenoxybenzamine (an (Yamaguchi et al. 1980; Reid 1984 (Share 1983). Although the increase in plasma AVP caused by iv infusion of ANG II in dogs was abolished by a dopamine inhibitor haloperidol (Brooks & Claybaugh 1982) , antidiuresis produced by intraven¬ tricular (ivt) injection of ANG II in rats was not inhibited by haloperidol or an alpha-adrenergic blocking agent phentolamine (Hoffman et al. 1977 ).
The present study was designed to elucidate roles of catecholamines in the central action of (Fig. 1) or phenoxybenzamine (Fig. 2) (Fig. 2) . Pre-administration of 0.15 pmol propranolol followed by injection of 
(7)
+ (7) (9) (6) (Fig. 2) .
Plasma osmolality, concentrations of sodium, potassium and chloride, and haematocrit of the control group given ACSF twice were 292 ± 1 mosm/kg H20, 136.3 ± 0.4 mmol/1, 7.1 ± 0.4 mmol/1, 103.9 ± 1.0 mmol/1 and 42 ± 1%, re¬ spectively, 90 sec after the second injection of ACSF, and 291 ± 1, 136.4 ± 0.4, 7.2 ± 0.1, 101.0 ± 0.5 and 42 ± 1, respectively, 5 min after. Between the controls and all the groups in Figs. 1 and 2 there were no significant differences in the values of the plasma variables, except plasma sodium (132.3 ± 0.6 mmol/1, < 0.01) and potas¬ sium (8.6 ± 0.4 mmol/1, < 0.05) in the lactic acid solution plus ACSF group, and plasma osmolality (287 ± 1 mosm/kg, < 0.01) and sodium (137.8 ± 0.4 (Fig. 3) . The potency of ANG II in increasing plasma AVP in rats pre-injected with 0.4% lactic acid solution was similar to that in the animals pre-injected with ACSF. Haloperidol (0.15 pmol) given 10 min prior to the application of ANG II significantly (P < 0.01) inhibited the plasma AVP response to ANG II, whereas after the pre-injection of 0.15 pmol phenoxybenzamine or propranolol the plasma AVP response to ANG II was unaffected (Fig. 3) . The plasma AVP value in the haloperidol plus ANG II group (3.5 ± 0.8 ng/1) was signifi¬ cantly (P < 0.05) higher than that in the haloperi¬ dol plus ACSF group (1.7 ± 0.3 ng/1) shown in Fig. 1 (Bridges et al. 1976; Brooks et al. 1986a,b) , it may be possible that ANG Il-induced AVP release (Yamaguchi et al. 1980 ) is mediated and/or modu¬ lated by the catecholamines. This problem, how¬ ever, has not been fully investigated so far. The aim of the present study was pharmacologically to evaluate the roles of the catecholamines in AVP release in response to centrally applied ANG II. Although there are numerous studies on cen¬ tral effect of dopamine or noradrenaline on AVP release, the obtained results are conflicting:
These catecholamines had no effect on, could stimulate, or could inhibit AVP release (Share 1983 (Brooks et al. 1986a ). We found that plasma AVP was significantly increased 90 sec after the application of dopamine (Fig. 1) , consistent with the observation in urethane-anesthetized rats (Forsling & Williams 1984) . Similarly, we con¬ firmed the potency of phenylephrine in augmen¬ ting plasma AVP in conscious rats (Brooks et al. 1986a,b) (Fig. 2) (Yamaguchi et al. 1980 ). The effect of ANG II was significantly diminished by pre-treatment with the dopamine blocker haloperidol (Fig. 3) which actually abolished the effect of this catecho¬ lamine (Fig. 1) (Fig. 3) which abolished the effect of the alpha-1 agonist phenylephrine (Fig. 2) . There¬ fore, dopamine rather than noradrenaline may preferentially participate in the ANG II-induced AVP release, although there remains a question concerning the specificity of haloperidol as a dopamine antagonist. On the other hand, admini¬ stration of haloperidol (Fig. 1) , phenoxybenza¬ mine or propranolol alone (Fig. 2) (Miselis et al. 1979; Carithers et al. 1980; Carithers & Johnson 1985) .
